HUI CAO,Shili Wang,Yaohui Liu. Antitumor and vascular effects of apatinib combined with chemotherapy in mice with non-small-cell lung cancer. Oncol Transl Med, 2021, 7: 141-147. |
Antitumor and vascular effects of apatinib combined with chemotherapy in mice with non-small-cell lung cancer |
Received:November 03, 2020 Revised:June 22, 2021 |
View Full Text View/Add Comment Download reader |
KeyWord:non-small-cell lung cancer (NSCLC); apatinib; pemetrexed |
Author Name | Affiliation | E-mail | HUI CAO | Department of Pharmacy, Zigong Fourth People''s Hospital, Zigong 643000, China | benbenda3321@163.com | Shili Wang | Department of Pharmacy, Zigong Fourth People''s Hospital, Zigong 643000, China | | Yaohui Liu | Department of Pharmacy, Zigong First People''s Hospital, Zigong 643000, China | |
|
Hits: 3850 |
Download times: 4013 |
Abstract: |
Objective The aim of this study was to investigate the antitumor and vascular effects of apatinib use
combined with chemotherapy on mice with non-small-cell lung cancer (NSCLC).
Methods First, 60 tumor-bearing nude mice were randomly divided into control, low-dose, and high-dose
groups. Four nude mice per group were sacrificed before administration and on days 1, 3, 7, and 10 after
administration. HIF-1α expression in tumor tissues was detected. Second, 32 nude mice were randomly
divided into control, premetrexed, synchronous, and sequential groups. The weights and tumor volumes of
mice were recorded.
Results (1) HIF-1α expression decreased significantly on days 3 and 7 after low-dose apatinib treatment.
There was no significant difference in HIF-1α expression in the high-dose apatinib group (P > 0.05). MMP-
2 and MMP-9 expression levels in the low-dose apatinib group were significantly lower than those in the
control group (P < 0.05). (2) In the low-dose apatinib group, the microvessel density increased gradually
from days 3 to 7 post-treatment, while that in the high-dose apatinib group decreased significantly. (3) The
inhibitory effect of sequential therapy using low-dose apatinib and pemetrexed was optimal, while that of
synchronous treatment was not better than that of pemetrexed usage alone. Sequential treatment using
low-dose apatinib and pemetrexed exerted the best antitumor effect. (4) The expression levels of p-AKT,
p-mTOR, p-MEK, and p-ERK in the sequential group were significantly lower than those in the other three
groups (P < 0.05).
Conclusion Apatinib usage involves certain considerations, such as dose requirements and time window
for vascular normalization during lung cancer treatment in nude mice, suggesting that dynamic contrastenhanced magnetic resonance imaging and other tests can be conducted to determine the vascular
normalization window in patients with lung cancer and to achieve the optimal anti-vascular effect. |
Close |
|
|
|